Patients whose Type 2 diabetes is not controlled with metformin can benefit long-term from a two-drug combination treatment that also reduces weight.
Wistar scientists have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein.
"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT
A radioisotope researcher in the Radioisotope Science and Technology Division at the Department of Energy’s Oak Ridge National Laboratory, Davern is focusing on ways to use nanoparticles — particles 100 nanometers or smaller that can have special properties — to contain those radioisotopes and deliver them directly to cancer cells, where they can decay into different isotopes that irradiate those cells.
Researchers have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease
Researchers from NUS Engineering have developed a novel conversion approach that marries chemical and biological processes to produce high-value amino acids such as L-DOPA and L-Proline from low-cost, abundant waste material like crustacean shells and sawdust.
In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.
Michigan State University Foundation Professor Guowei Wei wasn’t preparing machine learning techniques for a global health crisis. Still, when one broke out, he and his team were ready to help.
Dr. Edward Jones-Lopez, joins a Newswise Live Expert Panel on Thursday Oct. 29, from 3-4 PM EDT to discuss the AstraZenea COVID-19 vaccine trial.
Nationalistic behaviour by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organisation RAND Europe.
University at Buffalo spinoff Cytocybernetics is developing a high-tech tool called CyberQ to rapidly assess whether or not investigational COVID-19 drugs have arrhythmogenic properties that can result in sudden cardiac death.
A medication used to treat motor neuron diseases, like Lou Gehrig’s disease, might also have the potential to help treat post-traumatic stress disorder (PTSD), particularly the symptoms linked to suicide attempts, according to a study, “Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms,” published Oct. 27 in the Journal of Clinical Psychiatry by researchers at the Uniformed Services University of the Health Sciences (USU).
Women with epilepsy who take the antiseizure drug valproic acid while pregnant are at more than double the risk of having children with autism spectrum disorder and nearly double the risk of having children with attention deficit hyperactivity disorder (ADHD), according to a study in the October 28, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effect.
Patients with diabetic kidney disease can potentially be treated with a new investigational medication that may slow the progress of their illness without harmful side effects to their hearts, according to the results of a global clinical trial announced Friday.
The prescription of potentially inappropriate medications to older adults is linked to increased hospitalizations, and it costs patients, on average, more than $450 per year, according to a new University at Buffalo study.
Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM).
The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a new study led by researchers at Massachusetts General Hospital (MGH).
University of Minnesota Medical School physician researchers studied hydroxychloroquine as a treatment to prevent COVID-19 for those with high-risk for exposure to the virus - health care workers.
A new phase 2 clinical trial found the drug axitinib was able to extend the lives of patients with incurable head and neck cancer by several months, and also identified a subset of patients with a specific mutation for whom the drug is likely to work best.
Sex, age, and severity of disease may be useful in identifying COVID-19 survivors who are likely to have high levels of antibodies that can protect against the disease.
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
With specialized knowledge about medications and how they work to fight cancer, oncology pharmacists and pharmacy technicians play a vital role in patient care and research.
Texas Biomedical Research Institute (Texas Biomed) Professor Luis Martinez-Sobrido, Ph.D., recently released study findings, alongside colleagues at the University of Alabama at Birmingham and Aridis Pharmaceuticals, Inc. indicating that a human monoclonal antibody (hmAb) 1212C2 showed promise for further clinical development for preventative use or as a therapy for SARS-CoV-2, the virus that causes COVID-19. Earlier this year, the consortium of scientists isolated specific B cells from patients infected with SARS-CoV-2 and developed a panel of hmAbs that not only bind to SARS-CoV-2 infected cells, but also neutralize the ability of the virus to infect cells. The hmAb 1212C2 was subsequently licensed to Aridis Pharmaceuticals.
A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS). Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Receiving mail-order prescriptions on time is critical during the ongoing pandemic, as older adults and people with chronic conditions are avoiding leaving their homes.
There is some hope on the horizon for patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. More than a dozen members of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) were authors on a study announcing the results showing promise in the fight against ALS that appeared in AANEM’s journal Muscle & Nerve.
Toxicological Sciences features leading research biotransformation, toxicokinetics, and pharmacokinetics; computational toxicology and databases; mixtures toxicology; and more in the October 2020 issue.
There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.
A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.
The NCCN Oncology Research Program (ORP) plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2), supported by a $2-million grant from Puma Biotechnology, Inc.
UCLA researchers have found that a drug that activates the body’s natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center (VUMC) and optimized by AstraZeneca.
A first of its kind drug called vosoritide may increase bone growth in children with achondroplasia, the most common form of dwarfism, according to findings from a recent clinical trial published in The Lancet.
A team led by Penn Medicine has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom. The team hopes to develop the molecules into new bacteria-killing drugs, an important advancement considering increasing numbers of antibiotic-resistant bacteria which can cause illness such as sepsis and tuberculosis.
The raging lung inflammation that can contribute to death from the flu can be stopped in its tracks by a drug derived from a naturally occurring human protein, a new animal study suggests.
In a new COVID-19 clinical trial, Stuart Cohen at UC Davis Health evaluates the efficacy, safety and tolerability of monoclonal antibody combination in adults exposed to patients with COVID-19. It is the same antibody drug given to President Trump to treat his COVID-19.
A COVID-19 vaccine candidate that underwent extensive preclinical testing this spring and summer shows potent preclinical immune responses — including several that distinguish it from other COVID-19 vaccine approaches — according to a preprint deposited in the BioRxiv repository.
The Society for Obstetric Anesthesia and Perinatology (SOAP),the American Society of Anesthesiologists (ASA), the Society for Pediatric Anesthesia (SPA) the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) aim to clearly reassure pregnant women that the article “Association Between Epidural Analgesia During Labor and Risk of Autism Spectrum Disorders in Offspring,” a new retrospective database study published in JAMA Pediatrics on October 12th, 2020 does not provide credible scientific evidence that epidurals for pain relief cause autism.
Scientists at Wake Forest School of Medicine have recorded real time changes in dopamine and serotonin levels in the human brain that are involved with perception and decision-making. These same neurochemicals also are critical to movement disorders and psychiatric conditions, including substance abuse and depression.
Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, has been selected as an authorized treatment center to offer brexucabtagene autoleucel, also known by the brand name TecartusTM. It is the first and only chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
A University of Delaware research team has devised tiny cargo-carrying systems many times smaller than a human hair, made from molecules called peptides that help provide structure for cells and tissues. The team has reported advances in the nanoparticle design that allow them to control the shape of the nanoparticles to allow them to better bind to tissue in the body and stay in a particular location.
The drug discovery program is focused on the assessment of hundreds of drug candidates in the CDI labs, to find the most promising potential therapies.
Media invited to live Q&A on Oct 7th, 2pm EDT
A pay-for performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers report in a new study published online in the Journal of Clinical Oncology.
A patient at UH Cleveland Medical Center received an AAV8-mediated gene transfer of human Ornithine Transcarbamylase. The infusion was well tolerated and patient was discharged without issue. The gene therapy is part of an international, multi-site trial sponsored by Ultragenyx Pharmaceutical Inc.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right